We are live on
!
Find out more
VPC
Vestal Point Capital Portfolio holdings
AUM
$3.58B
1-Year Est. Return
189.12%
This Fund
S&P 500
This Quarter
Est. Return
+30.09%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$944M
AUM Growth
–
Cap. Flow
+$791M
Cap. Flow
% of AUM
83.77%
Top 10 Holdings %
Top 10 Hldgs %
61.64%
Holding
48
New
48
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$92.1M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$90.5M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$62.3M |
| 4 |
Merck
MRK
|
+$41.5M |
| 5 |
Globus Medical
GMED
|
+$39M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$18.4B
| $105M | 11.17% |
+800,000
| New | +$92.1M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$16.1B
| $89.2M | 9.45% |
+725,000
| New | +$90.5M |
|
|
3
Ascendis Pharma A/S
ASND
$16.7B
| $78.7M | 8.34% |
+625,000
| New | +$62.3M |
|
|
INBX
4
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $58.1M | 6.16% |
+1,530,000
| New | +$32.8M |
|
|
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
| $52.3M | 5.54% |
+1,300,000
| New | +$37M |
|
|
6
Merck
MRK
$326B
| $43.6M | 4.62% |
+400,000
| New | +$41.5M |
|
|
7
Globus Medical
GMED
$10.9B
| $42.6M | 4.52% |
+800,000
| New | +$39M |
|
8
Pacira BioSciences
PCRX
$1.05B
| $40.5M | 4.29% |
+1,200,000
| New | +$35.1M |
|
|
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
| $38.4M | 4.07% |
+1,625,000
| New | +$28.9M |
|
10
Vaxcyte
PCVX
$7.88B
| $33M | 3.49% |
+525,000
| New | +$27.3M |
|
11
Insmed
INSM
$22.6B
| $27.9M | 2.95% |
+900,000
| New | +$23.3M |
|
12
uniQure
QURE
$2.52B
| $26.6M | 2.82% |
+3,925,000
| New | +$25.9M |
|
13
ALX Oncology
ALXO
$268M
| $24.6M | 2.61% |
+1,655,000
| New | +$15.7M |
|
14
Immatics
IMTX
$1.19B
| $22.1M | 2.34% |
+2,100,000
| New | +$19.3M |
|
15
Viridian Therapeutics
VRDN
$2.15B
| $21.8M | 2.31% |
+1,000,000
| New | +$15.8M |
|
16
Revolution Medicines
RVMD
$39.1B
| $20.8M | 2.2% |
+725,000
| New | +$17.4M |
|
17
Biogen
BIIB
$30.4B
| $19.4M | 2.06% |
+75,000
| New | +$18.4M |
|
18
Edwards Lifesciences
EW
$48.2B
| $17.2M | 1.82% |
+225,000
| New | +$15.7M |
|
19
AstraZeneca
AZN
$267B
| $16.8M | 1.78% |
+125,000
| New | +$16.2M |
|
20
Crinetics Pharmaceuticals
CRNX
$8.88B
| $16M | 1.7% |
+450,000
| New | +$13.8M |
|
|
LYRA
21
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $15.7M | 1.67% |
+60,000
| New | +$10.9M |
|
22
Sanofi
SNY
$109B
| $14.9M | 1.58% |
+300,000
| New | +$14.7M |
|
|
NUVL
23
DELISTED
Nuvalent
NUVL
| $14.7M | 1.56% |
+200,000
| New | +$12.4M |
|
|
APLT
24
DELISTED
Applied Therapeutics
APLT
| $13.9M | 1.47% |
+4,155,000
| New | +$10.3M |
|
25
Liquidia Corp
LQDA
$7.72B
| $12.3M | 1.31% |
+1,025,000
| New | +$7.38M |
|
Similar funds
WWA
BPS
RSWM
SPC
U
SL
AAP
SCM
Vestal Point Capital's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Vestal Point Capital, which disclosed 48 positions worth $944M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is Neurocrine Biosciences: 800,000 shares worth $105M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Vestal Point Capital's largest Q4 2023 buy was Neurocrine Biosciences: 800,000 shares worth $105M.
- Vestal Point Capital's ten largest holdings make up 62% of its $944M portfolio in Q4 2023.
- Vestal Point Capital disclosed 48 positions in Q4 2023, its first 13F filing on record.
Based on Vestal Point Capital's 13F filing for Q4 2023, filed 13 Feb 2024.